Celltrion BioSolutions launched to venture into CDMO

Q: How long will it take to read this news story?

The story "Celltrion BioSolutions launched to venture into CDMO" has 538 words across 29 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Celltrion BioSolutions launched to venture into CDMO" was covered 5 days ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 0 news stories per day. It's most recent story was published 2 days ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24576930</li><li>URL: https://beamstart.com/news/celltrion-biosolutions-launched-to-venture-1734805</li></ul>

Korea Economic Daily Logo Korea Economic Daily 5d ago

Celltrion BioSolutions launched to venture into CDMO - Korea Economic Daily

Quick Summary:

In line with demand, it may build a new CDMO plant abroad.“We have received requests continuously from small domestic and foreign bio firms to develop and produce their drug candidate substances,” Seo said in a press conference.“We have also received many requests from the world’s large cancer hospitals to provide CGT-specific services, so we decided to start our CDMO business".

DIFFERENTIATION STRATEGYTo differentiate itself from rivals such as Samsung Biologics Co.and Switzerland-based Lonza, the world’s No.1 CDMO company, Seo stressed that Celltrion BioSolutions will produce a variety of drug modalities — from monoclonal to trispecific antibody drugs, subcutaneous injection formulation and CGT.

Seo expressed confidence about its venture into the CDMO market, saying its experience in the development, production and sale of biosimilars will give it an edge.“I think Lonza and Celltrion are the only companies that can provide all types of CDMO services,” he added.